The Danish pharmaceutical company Novo Nordisk reported a net profit of 28.23 billion Danish kroner in the fourth quarter, exceeding the expected 26.09 billion. The total net profit for the entire year reached 100.99 billion kroner, surpassing forecasts. The company recorded a 107% increase in sales of the obesity drug Wegovy, although slightly below analysts’ expectations. Novo Nordisk is leveraging the growing global demand for GLP-1 agonists for obesity treatment, while investors await news on other candidates.
Novo Nordisk made more money than expected due to high demand.
